KKR-backed Biosynth Carbosynth Acquires vivitide and Welcomes Ampersand Capital Partners as New Shareholder
Combination of Biosynth Carbosynth and vivitide creates global life sciences platform serving high-growth biopharma and diagnostics end-markets.